Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; crospovidone; microcrystalline cellulose; hypromellose; purified talc; macrogol 4000; iron oxide yellow - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide yellow - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 6.94 mg (equivalent: amlodipine, qty 5 mg) - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 4000 - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg); hydrochlorothiazide, quantity: 25 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; hypromellose; purified talc; macrogol 4000; iron oxide yellow - amlodipine/valsartan/hct novartis is indicated only as substitution therapy for the treatment of hypertension in patients whose blood pressure is already adequately controlled on the triple combination of amlodipine, valsartan and hydrochlorothiazide taken either as three single component formulations or as dual-component formulation with a single component formulation, all components at the same dose level. treatment should not be initiated with these fixed-dose combinations (see dosage and administration).

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amlodipine; valsartan; hydrochlorothiazide - film-coated tablet - 10/160/12.5 milligram(s) - valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amlodipine; valsartan; hydrochlorothiazide - film-coated tablet - 10/160/25 milligram(s) - valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amlodipine; valsartan; hydrochlorothiazide - film-coated tablet - 10/320/25 milligram(s) - valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amlodipine; valsartan; hydrochlorothiazide - film-coated tablet - 5/160/12.5 milligram(s) - valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - amlodipine; valsartan; hydrochlorothiazide - film-coated tablet - 5/160/25 milligram(s) - valsartan, amlodipine and hydrochlorothiazide

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - amlodipine besilate; valsartan; hydrochlorothiazide - film-coated tablet - 10/160/12.5 milligram(s) - angiotensin ii antagonists, other combinations; valsartan, amlodipine and hydrochlorothiazide